JP2016501528A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501528A5 JP2016501528A5 JP2015546782A JP2015546782A JP2016501528A5 JP 2016501528 A5 JP2016501528 A5 JP 2016501528A5 JP 2015546782 A JP2015546782 A JP 2015546782A JP 2015546782 A JP2015546782 A JP 2015546782A JP 2016501528 A5 JP2016501528 A5 JP 2016501528A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- viral particle
- protein
- isolated viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA2012/050893 WO2014089668A1 (en) | 2012-12-12 | 2012-12-12 | Compositions and methods for the treatment of brain cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501528A JP2016501528A (ja) | 2016-01-21 |
| JP2016501528A5 true JP2016501528A5 (enExample) | 2016-03-03 |
| JP6162818B2 JP6162818B2 (ja) | 2017-07-12 |
Family
ID=50933623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015546782A Expired - Fee Related JP6162818B2 (ja) | 2012-12-12 | 2012-12-12 | 脳癌の治療のための組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150307559A1 (enExample) |
| EP (1) | EP2931880B1 (enExample) |
| JP (1) | JP6162818B2 (enExample) |
| CN (1) | CN105008524A (enExample) |
| AU (1) | AU2012396787B9 (enExample) |
| BR (1) | BR112015013669A2 (enExample) |
| CA (1) | CA2894618A1 (enExample) |
| IL (1) | IL239374B (enExample) |
| MX (1) | MX366493B (enExample) |
| RU (1) | RU2705244C2 (enExample) |
| WO (1) | WO2014089668A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011070440A2 (en) | 2009-12-10 | 2011-06-16 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| US9364532B2 (en) | 2011-06-08 | 2016-06-14 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Compositions and methods for glioblastoma treatment |
| JP2016513115A (ja) | 2013-02-21 | 2016-05-12 | チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド | ワクチン組成物 |
| CN110636853B (zh) * | 2017-05-19 | 2024-10-18 | 佐治亚州立大学研究基金会公司 | 重组溶瘤病毒 |
| SI3684786T1 (sl) | 2017-09-22 | 2025-03-31 | Centre National De La Recherche Scientifique (Cnrs) | Mutirani glikoprotein virusa vezikularnega stomatitisa |
| DE102018215551A1 (de) | 2018-09-12 | 2020-03-12 | Virolutions Biotech Gmbh | Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten |
| CN112442114A (zh) * | 2019-08-29 | 2021-03-05 | 渥太华Hdl药物研发公司 | 一种多肽及其应用 |
| EP4288140A1 (en) | 2021-02-05 | 2023-12-13 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
| AU2024353718A1 (en) | 2023-09-25 | 2026-04-09 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ2003784A3 (cs) * | 2000-09-22 | 2003-11-12 | Virxsys Corporation | Zlepšené podmíněně se replikující vektory, způsoby jejich produkce a jejich použití |
| CN102026645B (zh) * | 2006-09-15 | 2016-01-27 | 渥太华医院研究机构 | 溶瘤弹状病毒 |
| DE102008050860A1 (de) | 2008-10-08 | 2010-04-15 | Dorothee Von Laer | LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren |
-
2012
- 2012-12-12 US US14/651,761 patent/US20150307559A1/en not_active Abandoned
- 2012-12-12 JP JP2015546782A patent/JP6162818B2/ja not_active Expired - Fee Related
- 2012-12-12 WO PCT/CA2012/050893 patent/WO2014089668A1/en not_active Ceased
- 2012-12-12 RU RU2015128078A patent/RU2705244C2/ru active
- 2012-12-12 MX MX2015007093A patent/MX366493B/es active IP Right Grant
- 2012-12-12 CN CN201280077698.6A patent/CN105008524A/zh active Pending
- 2012-12-12 AU AU2012396787A patent/AU2012396787B9/en not_active Ceased
- 2012-12-12 EP EP12889818.6A patent/EP2931880B1/en not_active Not-in-force
- 2012-12-12 CA CA2894618A patent/CA2894618A1/en not_active Abandoned
- 2012-12-12 BR BR112015013669A patent/BR112015013669A2/pt not_active Application Discontinuation
-
2015
- 2015-06-11 IL IL239374A patent/IL239374B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Araste et al. | Peptide-based targeted therapeutics: Focus on cancer treatment | |
| RU2015128078A (ru) | Композиции и способы лечения рака мозга | |
| Resnier et al. | A review of the current status of siRNA nanomedicines in the treatment of cancer | |
| Ibraheem et al. | Administration strategies for proteins and peptides | |
| JP2015518818A5 (enExample) | ||
| JP2012041342A5 (enExample) | ||
| JP2014512171A5 (enExample) | ||
| JP2017031213A5 (enExample) | ||
| JP2013542205A5 (enExample) | ||
| JP2016526531A5 (enExample) | ||
| JP2015514115A5 (enExample) | ||
| JP2013541583A5 (enExample) | ||
| Shen et al. | Rhein augments antiproliferative effects of atezolizumab based on breast cancer (4T1) regression | |
| JP2019531293A5 (enExample) | ||
| SI2823048T1 (en) | A new drug delivery system based on JCV-VLP | |
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| JP2014530246A5 (enExample) | ||
| JP2017502058A5 (enExample) | ||
| JP2012517459A5 (enExample) | ||
| FI3919060T3 (fi) | Ecopipam touretten oireyhtymän hoitoon | |
| Hegde et al. | To market, to market—2008 | |
| WO2013130672A3 (en) | Improved cancer treatments and diagnostics | |
| Maseda et al. | Use of fidaxomicin through a nasogastric tube for the treatment of septic shock caused by Clostridium difficile infection in a patient with oral cancer admitted to the Surgical Critical Care Unit | |
| EA200900214A1 (ru) | Фармацевтическая композиция рифабутина для лечения туберкулеза, способ ее получения и способ лечения | |
| JP2017508455A5 (enExample) |